This Bacterial and Plasmid Vectors market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The bacterial & plasmid vectors market size has grown rapidly in recent years. It will grow from $0.72 billion in 2024 to $0.82 billion in 2025 at a compound annual growth rate (CAGR) of 13%. The growth in the historic period can be attributed to rising prevalence of chronic diseases, prevalence of infectious diseases, aging population, increased healthcare spending, government initiatives, increased awareness of preventive healthcare.
The bacterial & plasmid vectors market size is expected to see rapid growth in the next few years. It will grow to $1.31 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to rising demand for point-of-care testing, gene and cell therapy, synthetic biology, crispr-cas technology, increased bioproduction, environmental and agricultural applications, expansion of biomanufacturing, growing focus on personalized medicine. Major trends in the forecast period include customized vector solutions, safety and ethical considerations, advanced vector delivery methods, data integration and analysis, viral vector alternatives, vector customization services, vector delivery optimization.
The bacterial & plasmid vectors market is expected to witness increased demand in the forthcoming years due to the rising prevalence of cancer and infectious diseases. Bacteria serve as essential vectors for delivering recombinant proteins into target cells, aiding in the treatment of cancer and various infectious diseases. For example, a report published by the American Cancer Society, a US-based non-profit organization, in April 2024 highlighted that approximately 609,000 cancer-related deaths occurred in 2022, with an estimated 1.9 million new cancer cases identified in the United States. The report further projected around 620,000 cancer deaths in 2024, indicating a slight increase in mortality rates. As a result, the rising prevalence of cancer and various infectious diseases, combined with the growing demand for bacterial and plasmid vectors for gene therapy, is expected to drive revenue growth in the bacterial and plasmid vectors market.
The growth of the bacterial and plasmid vectors market is expected to be propelled by the increasing number of clinical trials. Clinical trials refer to research studies involving human volunteers aimed at assessing the safety and efficacy of medical treatments, interventions, drugs, therapies, devices, or diagnostic procedures. These trials specifically evaluate the safety and effectiveness of Bacterial and Plasmid Vectors when used as part of therapeutic interventions, typically involving testing the vectors in human subjects to assess their ability to deliver therapeutic genes or gene-editing tools to target cells without causing harm. For instance, a report from Xtalks, a Canada-based digital health company, revealed that by May 17, 2023, a total of 452,604 clinical studies were registered on ClinicalTrials.gov, with 64,838 actively seeking participants. This marked a substantial increase compared to the more than 365,000 registered trials reported in early 2021. The rising number of clinical trials is a key driver stimulating the growth of the bacterial and plasmid vectors market.
Major players in the bacterial and plasmid vectors market are concentrating on developing advanced solutions, such as Adeno-Associated Viral (AAV) Vectors, to improve gene therapy applications and meet the rising demand for effective therapeutic options. An AAV vector is a virus-based vehicle used in gene therapy to deliver genetic material into target cells. For example, in March 2023, Charles River Laboratories, an India-based chemical manufacturer, introduced an off-the-shelf helper plasmid. This product offers several unique advantages, including immediate and reliable availability, consistent quality fit for purpose, kanamycin antibiotic resistance, animal component-free production, and royalty-free usage from research through to commercial stages. These features support the acceleration of production timelines for AAV-based gene therapies while streamlining complex supply chains in the manufacturing process.
Major companies in the bacterial and plasmid vectors market are increasingly focusing on developing advanced solutions, such as Innovative Plasmids, to optimize the production of adeno-associated virus (AAV) vectors. An innovative plasmid is a plasmid (a small, circular DNA molecule) that is specially designed or modified to perform specific advanced functions in biotechnology, gene therapy, or scientific research. For example, in March 2024, Polyplus, a France-based biotechnology company, launched the pPLUS AAV-RC2 plasmid. This new product aims to streamline the manufacturing process by offering a ready-to-use solution that enhances both the efficiency and reliability of vector production. Key features include a ready-to-use format optimized for AAV2 production, significant improvements in viral genome yield when paired with Polyplus transfection reagents, and high-quality manufacturing at a GMP-compliant facility.
In December 2022, Polyplus, a France-based biotechnology company, acquired Xpress Biologics for an undisclosed amount. This acquisition is part of Polyplus's strategy to expand its plasmid DNA engineering technology and services portfolio, thereby enhancing its capabilities in gene therapy and improving the manufacturing processes for advanced therapeutic products. Xpress Biologics, a Belgium-based biotechnology company, specializes in bacterial and plasmid vectors, further strengthening Polyplus's position in the biotechnology sector.
Bacterial and plasmid vectors are pivotal tools in molecular cloning, serving as the method to introduce recombinant DNA into a host cell. This process involves crafting DNA molecules and delivering them into a host cell. These vectors play a crucial role in transferring recombinant DNA into bacteria for the expression of proteins.
The primary categories in bacterial and plasmid vectors include E. coli expression vectors and other bacterial expression vectors. The E. coli expression system enables swift recombinant protein expression and subsequent cost-effective large-scale production. It is particularly advantageous for expressing antigens and functional proteins that are non-glycosylated. These techniques find applications in genetics, molecular biology, bioinformatics, and various sectors including hospitals, home care, specialty clinics, and others.
The bacterial and plasmid vectors market research report is one of a series of new reports that provides bacterial and plasmid vectors market statistics, including bacterial and plasmid vectors industry global market size, regional shares, competitors with a bacterial and plasmid vectors market share, detailed bacterial and plasmid vectors market segments, market trends and opportunities, and any further data you may need to thrive in the bacterial and plasmid vectors industry. This bacterial and plasmid vectors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
Major companies operating in the bacterial and plasmid vectors market include Sigma-Aldrich Inc., ATUM, QIAGEN N.V., Promega Corporation, Thermo Fisher Scientific Inc., GenScript Biotech Corporation, Takara Bio Inc., IBA GmbH, Bio-Rad Laboratories, New England Biolabs, Agilent Technologies, Life Technologies Corporation, Clontech Laboratories Inc., DNA TwoPointO Inc., F. Hoffmann-La Roche Ltd, Norgen Biotek Corporation, Tecan Group Ltd, Biotage, BioCat GmbH, BioChain Institute Inc., BioLegend, BioVision Inc., Cell Applications Inc., Cell Biolabs Inc., Cell Signaling Technology Inc., Clontech Laboratories Inc., Creative Biogene, Creative Biomart, Creative Diagnostics, Enzo Life Sciences Inc.
North America was the largest region in the bacterial & plasmid vectors market in 2024. The Middle East is expected to be the fastest-growing region in the global bacterial & plasmid vectors market share during the forecast period. The regions covered in the bacterial and plasmid vectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the bacterial and plasmid vectors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The bacterial and plasmid vectors market includes revenues earned by entities by cloning, transferring, and manipulating genes. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The bacterial & plasmid vectors market size has grown rapidly in recent years. It will grow from $0.72 billion in 2024 to $0.82 billion in 2025 at a compound annual growth rate (CAGR) of 13%. The growth in the historic period can be attributed to rising prevalence of chronic diseases, prevalence of infectious diseases, aging population, increased healthcare spending, government initiatives, increased awareness of preventive healthcare.
The bacterial & plasmid vectors market size is expected to see rapid growth in the next few years. It will grow to $1.31 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to rising demand for point-of-care testing, gene and cell therapy, synthetic biology, crispr-cas technology, increased bioproduction, environmental and agricultural applications, expansion of biomanufacturing, growing focus on personalized medicine. Major trends in the forecast period include customized vector solutions, safety and ethical considerations, advanced vector delivery methods, data integration and analysis, viral vector alternatives, vector customization services, vector delivery optimization.
The bacterial & plasmid vectors market is expected to witness increased demand in the forthcoming years due to the rising prevalence of cancer and infectious diseases. Bacteria serve as essential vectors for delivering recombinant proteins into target cells, aiding in the treatment of cancer and various infectious diseases. For example, a report published by the American Cancer Society, a US-based non-profit organization, in April 2024 highlighted that approximately 609,000 cancer-related deaths occurred in 2022, with an estimated 1.9 million new cancer cases identified in the United States. The report further projected around 620,000 cancer deaths in 2024, indicating a slight increase in mortality rates. As a result, the rising prevalence of cancer and various infectious diseases, combined with the growing demand for bacterial and plasmid vectors for gene therapy, is expected to drive revenue growth in the bacterial and plasmid vectors market.
The growth of the bacterial and plasmid vectors market is expected to be propelled by the increasing number of clinical trials. Clinical trials refer to research studies involving human volunteers aimed at assessing the safety and efficacy of medical treatments, interventions, drugs, therapies, devices, or diagnostic procedures. These trials specifically evaluate the safety and effectiveness of Bacterial and Plasmid Vectors when used as part of therapeutic interventions, typically involving testing the vectors in human subjects to assess their ability to deliver therapeutic genes or gene-editing tools to target cells without causing harm. For instance, a report from Xtalks, a Canada-based digital health company, revealed that by May 17, 2023, a total of 452,604 clinical studies were registered on ClinicalTrials.gov, with 64,838 actively seeking participants. This marked a substantial increase compared to the more than 365,000 registered trials reported in early 2021. The rising number of clinical trials is a key driver stimulating the growth of the bacterial and plasmid vectors market.
Major players in the bacterial and plasmid vectors market are concentrating on developing advanced solutions, such as Adeno-Associated Viral (AAV) Vectors, to improve gene therapy applications and meet the rising demand for effective therapeutic options. An AAV vector is a virus-based vehicle used in gene therapy to deliver genetic material into target cells. For example, in March 2023, Charles River Laboratories, an India-based chemical manufacturer, introduced an off-the-shelf helper plasmid. This product offers several unique advantages, including immediate and reliable availability, consistent quality fit for purpose, kanamycin antibiotic resistance, animal component-free production, and royalty-free usage from research through to commercial stages. These features support the acceleration of production timelines for AAV-based gene therapies while streamlining complex supply chains in the manufacturing process.
Major companies in the bacterial and plasmid vectors market are increasingly focusing on developing advanced solutions, such as Innovative Plasmids, to optimize the production of adeno-associated virus (AAV) vectors. An innovative plasmid is a plasmid (a small, circular DNA molecule) that is specially designed or modified to perform specific advanced functions in biotechnology, gene therapy, or scientific research. For example, in March 2024, Polyplus, a France-based biotechnology company, launched the pPLUS AAV-RC2 plasmid. This new product aims to streamline the manufacturing process by offering a ready-to-use solution that enhances both the efficiency and reliability of vector production. Key features include a ready-to-use format optimized for AAV2 production, significant improvements in viral genome yield when paired with Polyplus transfection reagents, and high-quality manufacturing at a GMP-compliant facility.
In December 2022, Polyplus, a France-based biotechnology company, acquired Xpress Biologics for an undisclosed amount. This acquisition is part of Polyplus's strategy to expand its plasmid DNA engineering technology and services portfolio, thereby enhancing its capabilities in gene therapy and improving the manufacturing processes for advanced therapeutic products. Xpress Biologics, a Belgium-based biotechnology company, specializes in bacterial and plasmid vectors, further strengthening Polyplus's position in the biotechnology sector.
Bacterial and plasmid vectors are pivotal tools in molecular cloning, serving as the method to introduce recombinant DNA into a host cell. This process involves crafting DNA molecules and delivering them into a host cell. These vectors play a crucial role in transferring recombinant DNA into bacteria for the expression of proteins.
The primary categories in bacterial and plasmid vectors include E. coli expression vectors and other bacterial expression vectors. The E. coli expression system enables swift recombinant protein expression and subsequent cost-effective large-scale production. It is particularly advantageous for expressing antigens and functional proteins that are non-glycosylated. These techniques find applications in genetics, molecular biology, bioinformatics, and various sectors including hospitals, home care, specialty clinics, and others.
The bacterial and plasmid vectors market research report is one of a series of new reports that provides bacterial and plasmid vectors market statistics, including bacterial and plasmid vectors industry global market size, regional shares, competitors with a bacterial and plasmid vectors market share, detailed bacterial and plasmid vectors market segments, market trends and opportunities, and any further data you may need to thrive in the bacterial and plasmid vectors industry. This bacterial and plasmid vectors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
Major companies operating in the bacterial and plasmid vectors market include Sigma-Aldrich Inc., ATUM, QIAGEN N.V., Promega Corporation, Thermo Fisher Scientific Inc., GenScript Biotech Corporation, Takara Bio Inc., IBA GmbH, Bio-Rad Laboratories, New England Biolabs, Agilent Technologies, Life Technologies Corporation, Clontech Laboratories Inc., DNA TwoPointO Inc., F. Hoffmann-La Roche Ltd, Norgen Biotek Corporation, Tecan Group Ltd, Biotage, BioCat GmbH, BioChain Institute Inc., BioLegend, BioVision Inc., Cell Applications Inc., Cell Biolabs Inc., Cell Signaling Technology Inc., Clontech Laboratories Inc., Creative Biogene, Creative Biomart, Creative Diagnostics, Enzo Life Sciences Inc.
North America was the largest region in the bacterial & plasmid vectors market in 2024. The Middle East is expected to be the fastest-growing region in the global bacterial & plasmid vectors market share during the forecast period. The regions covered in the bacterial and plasmid vectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the bacterial and plasmid vectors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The bacterial and plasmid vectors market includes revenues earned by entities by cloning, transferring, and manipulating genes. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Executive Summary
Bacterial and Plasmid Vectors Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on bacterial and plasmid vectors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for bacterial and plasmid vectors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bacterial and plasmid vectors market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Host Type: E.Coli Expression Vectors; Other Bacterial Expression Vectors2) By Application: Genetics; Molecular Biology; Bioinformatics; Other Applications
3) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By E. Coli Expression Vectors: PET Vectors; PUC Vectors; PBR322 Vectors; Expression Systems for Protein Production2) By Other Bacterial Expression Vectors: Bacillus Subtilis Vectors; Pseudomonas Vectors; Lactococcus Lactis Vectors; Streptomyces Vectors
Key Companies Mentioned: Sigma-Aldrich Inc.; ATUM; QIAGEN N.V.; Promega Corporation; Thermo Fisher Scientific Inc.
Countries: Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Bacterial and Plasmid Vectors market report include:- Sigma-Aldrich Inc.
- ATUM
- QIAGEN N.V.
- Promega Corporation
- Thermo Fisher Scientific Inc.
- GenScript Biotech Corporation
- Takara Bio Inc.
- IBA GmbH
- Bio-Rad Laboratories
- New England Biolabs
- Agilent Technologies
- Life Technologies Corporation
- Clontech Laboratories Inc.
- DNA TwoPointO Inc.
- F. Hoffmann-La Roche Ltd
- Norgen Biotek Corporation
- Tecan Group Ltd
- Biotage
- BioCat GmbH
- BioChain Institute Inc.
- BioLegend
- BioVision Inc.
- Cell Applications Inc.
- Cell Biolabs Inc.
- Cell Signaling Technology Inc.
- Clontech Laboratories Inc.
- Creative Biogene
- Creative Biomart
- Creative Diagnostics
- Enzo Life Sciences Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | April 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 0.82 Billion |
| Forecasted Market Value ( USD | $ 1.31 Billion |
| Compound Annual Growth Rate | 12.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
